Current patent and clinical status of stimulator of interferon genes (STING) agonists for cancer immunotherapy

Pharm Pat Anal. 2019 Jul;8(4):87-90. doi: 10.4155/ppa-2019-0013. Epub 2019 Jul 29.
No abstract available

Keywords: STING; cancer immunotherapy; cyclic dinucleotides; immune response; type I interferon.

Publication types

  • Editorial

MeSH terms

  • Animals
  • Antineoplastic Agents, Immunological / pharmacology
  • Antineoplastic Agents, Immunological / therapeutic use*
  • Humans
  • Immunotherapy
  • Interferon Regulatory Factor-3 / immunology
  • Membrane Proteins / agonists*
  • Neoplasms / drug therapy*
  • Neoplasms / immunology
  • Nucleotides / pharmacology
  • Nucleotides / therapeutic use
  • Nucleotidyltransferases / immunology
  • Patents as Topic
  • Signal Transduction

Substances

  • Antineoplastic Agents, Immunological
  • IRF3 protein, human
  • Interferon Regulatory Factor-3
  • Membrane Proteins
  • Nucleotides
  • STING1 protein, human
  • Nucleotidyltransferases
  • cGAS protein, human